TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Eql Pharma AB
Closing information (x1000 EUR)
| Closing information | 2025/03 (consolidated) | 2024/03 (consolidated) | 2023/03 (consolidated) |
| Turnover |
34,429
|
22,921
|
23,050 |
| Financial expenses |
1,200
|
497
|
210 |
| Earnings before taxes |
5,010
|
2,482
|
3,456 |
| EBITDA |
7,378
|
3,590
|
4,401 |
| Total assets |
74,553
|
32,430
|
25,337 |
| Current assets |
36,893
|
17,160
|
14,830 |
| Current liabilities |
20,372
|
14,061
|
10,285 |
| Equity capital |
20,374
|
15,421
|
13,724 |
| - share capital |
121
|
113
|
116 |
| Employees (average) |
21
|
21
|
18 |
Financial ratios
| Fiscal year | 2025/03 (consolidated) | 2024/03 (consolidated) | 2023/03 (consolidated) |
| Solvency |
27.3%
|
47.6%
|
54.2% |
| Turnover per employee |
1,639
|
1,091
|
1,281 |
| Profit as a percentage of turnover |
14.6%
|
10.8%
|
15.0% |
| Return on assets (ROA) |
8.3%
|
9.2%
|
14.5% |
| Current ratio |
181.1%
|
122.0%
|
144.2% |
| Return on equity (ROE) |
24.6%
|
16.1%
|
25.2% |
| Change turnover |
10,079
|
369
|
-13,288 |
| Change turnover % |
41%
|
2%
|
-37% |
| Chg. No. of employees |
0
|
3
|
5 |
| Chg. No. of employees % |
0%
|
17%
|
38% |
Total value of public sale
| Fiscal year | 2025/03 (consolidated) | 2024/03 (consolidated) | 2023/03 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.